RapidAI wins FDA clearance for LVO identification

By AuntMinnie.com staff writers

August 13, 2020 -- Artificial intelligence (AI) software developer RapidAI has received clearance from the U.S. Food and Drug Administration (FDA) for its software that detects suspected large-vessel occlusions (LVO).

Rapid LVO identifies suspected LVOs using vessel tracking and assessment of brain regions with reduced blood vessel density. It analyzes images in as few as three minutes and has a sensitivity of 97% and specificity of 96%, according to the company.


Copyright © 2020 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: